According to GuruFocus Insider Data, these are the largest CFO buys during the past week.
SVP and CFO of Jazz Pharmaceuticals Inc. (JAZZ, Financial) Kathryn E Falberg bought 50,000 shares on 08/31/2010 at an average price of $8.72. Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Jazz Pharmaceuticals Inc. has a market cap of $374.2 million; its shares were traded at around $9.71 with a P/E ratio of 23.7 and P/S ratio of 2.9.
Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. Total revenues for the quarter ended June 30, 2010 were $40.5 million, compared to $37.3 million for the quarter ended June 30, 2009. Total revenues included net product sales, royalties and contract revenues. Xyrem net sales for the second quarter of 2010 were $33.7 million, compared to $22.4 million for the second quarter of 2009, representing a 51 percent increase.
JAZZ is in the portfolios of Bruce Kovner of Caxton Associates.
Chairman and CEO Bruce C Cozadd, SVP and CFO Kathryn E Falberg, and Director Patrick G Enright bought shares of JAZZ stock.
Vestin Realty Mortgage II Inc. (VRTB, Financial): President, CEO & Interim CFO Michael V Shustek Bought 44,298 Shares
President, CEO & Interim CFO of Vestin Realty Mortgage II Inc. (VRTB) Michael V Shustek bought 44,298 shares on 08/26/2010 at an average price of $1.65. Vestin Realty Mortgage II, Inc., a real estate investment trust, invests in short-term loans secured by real estate through deeds of trust or mortgages. Vestin Realty Mortgage Ii Inc. has a market cap of $23.5 million; its shares were traded at around $1.73 with and P/S ratio of 3.7.
VRTB is in the portfolios of Chuck Royce of Royce& Associates.
President, CEO & Interim CFO Michael V Shustek bought shares of VRTB stock.
Aastrom Biosciences Inc. (ASTM, Financial): CFO Scott Durbin Bought 16,463 Shares
CFO of Aastrom Biosciences Inc. (ASTM) Scott Durbin bought 16,463 shares on 08/26/2010 at an average price of $1.45. Aastrom Biosciences, Inc. develops autologous cell products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell technology. Aastrom Biosciences Inc. has a market cap of $41.8 million; its shares were traded at around $1.48 with and P/S ratio of 469.9.
Aastrom Biosciences, Inc. reported operating results for the fourth quarter and fiscal year ended June 30, 2010. As of June 30, 2010, the company had a total of $19.1 million in cash, cash equivalents and short term investments, compared to $17.0 million in cash and equivalents at June 30, 2009. Net loss for the quarter ended June 30, 2010 was $5.1 million, or $0.18 per share, compared to a net loss of $4.0 million, or $0.20 per share, for the same period in fiscal year 2009.
CEO and President Timothy M Mayleben, CFO Scott Durbin, and Director George W Jr Dunbar bought ASTM stock.
Arrowhead Research Corp. (ARWR, Financial): CFO Kenneth Allen Myszkowski Bought 15,000 Shares
CFO of Arrowhead Research Corp. (ARWR) Kenneth Allen Myszkowski bought 15,000 shares on 08/27/2010 at an average price of $0.89. Arrowhead Research Corporation is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead Research Corp. has a market cap of $72.9 million; its shares were traded at around $1.03 with and P/S ratio of 19.1. Arrowhead Research Corp. had an annual average earning growth of 35.1% over the past 10 years.
Arrowhead Research Corporation announced financial results for its fiscal 2010 third quarter ended June 30, 2010. For the quarter ended June 30, 2010, Arrowhead reported revenue of $134,000, compared with $2.6 million in the quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2010 was $0.4 million, or $0.01 per share based on 64.6 million weighted average shares outstanding. This compares with a net loss of $2.5 million, or $0.6 per share based on 43.4 million weighted average shares outstanding, for the quarter ended June 30, 2009.
President and CEO Christopher Richard Anzalone and CFO Kenneth Allen Myszkowski bought shares of ARMR stock.
Consolidated Graphics Inc. (CGX, Financial): CFO & Accounting Officer Jon C Biro Bought 10,000 Shares
CFO & Accounting Officer of Consolidated Graphics Inc. (CGX) Jon C Biro bought 10,000 shares on 08/26/2010 at an average price of $37.68. Consolidated Graphics provides general commercial printing services. Consolidated Graphics Inc. has a market cap of $471.7 million; its shares were traded at around $42 with a P/E ratio of 17.7 and P/S ratio of 0.4.
CGX is in the portfolios of Jim Simons of Renaissance Technologies LLC.
CEO & Chairman of the Board, 10% Owner Joe R Davis, CFO & Accounting Officer Jon C Biro, and Director Hugh N West sold shares of CGX.
SVP and CFO of Jazz Pharmaceuticals Inc. (JAZZ, Financial) Kathryn E Falberg bought 50,000 shares on 08/31/2010 at an average price of $8.72. Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Jazz Pharmaceuticals Inc. has a market cap of $374.2 million; its shares were traded at around $9.71 with a P/E ratio of 23.7 and P/S ratio of 2.9.
Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. Total revenues for the quarter ended June 30, 2010 were $40.5 million, compared to $37.3 million for the quarter ended June 30, 2009. Total revenues included net product sales, royalties and contract revenues. Xyrem net sales for the second quarter of 2010 were $33.7 million, compared to $22.4 million for the second quarter of 2009, representing a 51 percent increase.
JAZZ is in the portfolios of Bruce Kovner of Caxton Associates.
Chairman and CEO Bruce C Cozadd, SVP and CFO Kathryn E Falberg, and Director Patrick G Enright bought shares of JAZZ stock.
Vestin Realty Mortgage II Inc. (VRTB, Financial): President, CEO & Interim CFO Michael V Shustek Bought 44,298 Shares
President, CEO & Interim CFO of Vestin Realty Mortgage II Inc. (VRTB) Michael V Shustek bought 44,298 shares on 08/26/2010 at an average price of $1.65. Vestin Realty Mortgage II, Inc., a real estate investment trust, invests in short-term loans secured by real estate through deeds of trust or mortgages. Vestin Realty Mortgage Ii Inc. has a market cap of $23.5 million; its shares were traded at around $1.73 with and P/S ratio of 3.7.
VRTB is in the portfolios of Chuck Royce of Royce& Associates.
President, CEO & Interim CFO Michael V Shustek bought shares of VRTB stock.
Aastrom Biosciences Inc. (ASTM, Financial): CFO Scott Durbin Bought 16,463 Shares
CFO of Aastrom Biosciences Inc. (ASTM) Scott Durbin bought 16,463 shares on 08/26/2010 at an average price of $1.45. Aastrom Biosciences, Inc. develops autologous cell products for the repair or regeneration of multiple human tissues, based on its proprietary Tissue Repair Cell technology. Aastrom Biosciences Inc. has a market cap of $41.8 million; its shares were traded at around $1.48 with and P/S ratio of 469.9.
Aastrom Biosciences, Inc. reported operating results for the fourth quarter and fiscal year ended June 30, 2010. As of June 30, 2010, the company had a total of $19.1 million in cash, cash equivalents and short term investments, compared to $17.0 million in cash and equivalents at June 30, 2009. Net loss for the quarter ended June 30, 2010 was $5.1 million, or $0.18 per share, compared to a net loss of $4.0 million, or $0.20 per share, for the same period in fiscal year 2009.
CEO and President Timothy M Mayleben, CFO Scott Durbin, and Director George W Jr Dunbar bought ASTM stock.
Arrowhead Research Corp. (ARWR, Financial): CFO Kenneth Allen Myszkowski Bought 15,000 Shares
CFO of Arrowhead Research Corp. (ARWR) Kenneth Allen Myszkowski bought 15,000 shares on 08/27/2010 at an average price of $0.89. Arrowhead Research Corporation is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead Research Corp. has a market cap of $72.9 million; its shares were traded at around $1.03 with and P/S ratio of 19.1. Arrowhead Research Corp. had an annual average earning growth of 35.1% over the past 10 years.
Arrowhead Research Corporation announced financial results for its fiscal 2010 third quarter ended June 30, 2010. For the quarter ended June 30, 2010, Arrowhead reported revenue of $134,000, compared with $2.6 million in the quarter ended June 30, 2009. Net loss for the quarter ended June 30, 2010 was $0.4 million, or $0.01 per share based on 64.6 million weighted average shares outstanding. This compares with a net loss of $2.5 million, or $0.6 per share based on 43.4 million weighted average shares outstanding, for the quarter ended June 30, 2009.
President and CEO Christopher Richard Anzalone and CFO Kenneth Allen Myszkowski bought shares of ARMR stock.
Consolidated Graphics Inc. (CGX, Financial): CFO & Accounting Officer Jon C Biro Bought 10,000 Shares
CFO & Accounting Officer of Consolidated Graphics Inc. (CGX) Jon C Biro bought 10,000 shares on 08/26/2010 at an average price of $37.68. Consolidated Graphics provides general commercial printing services. Consolidated Graphics Inc. has a market cap of $471.7 million; its shares were traded at around $42 with a P/E ratio of 17.7 and P/S ratio of 0.4.
CGX is in the portfolios of Jim Simons of Renaissance Technologies LLC.
CEO & Chairman of the Board, 10% Owner Joe R Davis, CFO & Accounting Officer Jon C Biro, and Director Hugh N West sold shares of CGX.
